BHIC (BioScience Health Innovations) LT-Debt-to-Total-Asset: 0.20 (As of Mar. 2026)


BHIC BioScience Health Innovations Inc BHIC
45 GF Score
Price $4.22
GF Value $164.84
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is BioScience Health Innovations LT-Debt-to-Total-Asset?

BioScience Health Innovations BHIC -0.80% 45 LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus rates BHIC with a GF Score™ of 45/100 and a GF Value™ of $164.84 (Possible Value Trap). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioScience Health Innovations's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.20.

BioScience Health Innovations's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.20). It may suggest that BioScience Health Innovations is progressively becoming more dependent on debt to grow their business.

BioScience Health Innovations  (OTCPK:BHIC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioScience Health Innovations LT-Debt-to-Total-Asset Related Terms

BioScience Health Innovations LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for BioScience Health Innovations's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioScience Health Innovations LT-Debt-to-Total-Asset Chart

BioScience Health Innovations Annual Data
Trend Aug19 Aug20 Aug21 Aug22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

BioScience Health Innovations Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.20
BHIC
45GF Score
BioScience Health Innovations Inc BHIC
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioScience Health Innovations LT-Debt-to-Total-Asset Calculation

BioScience Health Innovations's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0/1.707
=0.00

BioScience Health Innovations's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.46/2.33
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.20 mean?
BioScience Health Innovations (BHIC) has a LT-Debt-to-Total-Asset of 0.20 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioScience Health Innovations and its competitors.
Is BioScience Health Innovations' LT-Debt-to-Total-Asset too high?
BioScience Health Innovations' current LT-Debt-to-Total-Asset is 0.20. Overall, BioScience Health Innovations has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' LT-Debt-to-Total-Asset compare to SHFH and PETS?
BioScience Health Innovations' LT-Debt-to-Total-Asset of 0.20 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?
A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on BioScience Health Innovations and its competitors. BioScience Health Innovations's current LT-Debt-to-Total-Asset is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.22 — trading 97.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.20. BioScience Health Innovations' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioScience Health Innovations (BHIC) Overvalued in 2026?

Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued. The current stock price of $4.22 is trading 97.4% below its estimated GF Value™ of $164.84. GuruFocus considers BioScience Health Innovations to be Possible Value Trap.

Key valuation signals for BHIC:

  • LT-Debt-to-Total-Asset: 0.20
  • GF Value™: $164.84 vs. price of $4.22 (97.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioScience Health Innovations Business Description

Address 14857 South Concord Park Drive, Bluffdale, UT, USA, 84065
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
45GF Score

Get the complete analysis for BHIC

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.22
Price
$164.84
GF Value